Perspective Therapeutics ... (CATX)
undefined
undefined%
At close: undefined
3.48
0.87%
After-hours Dec 13, 2024, 08:00 PM EST

Company Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.

The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

It sells its products to facilities or physician practices that utilize various surgical facilities.

The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.

Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Perspective Therapeutics Inc.
Perspective Therapeutics Inc. logo
Country United States
IPO Date Nov 10, 2005
Industry Medical - Devices
Sector Healthcare
Employees 116
CEO Johan M. Spoor

Contact Details

Address:
350 Hills Street
Richland, Washington
United States
Website https://www.perspectivetherapeutics.com

Stock Details

Ticker Symbol CATX
Exchange NYSE
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000728387
CUSIP Number n/a
ISIN Number US46489V1044
Employer ID 41-1458152
SIC Code 3841

Key Executives

Name Position
Johan M. Spoor Chief Executive Officer & Director
Jonathan R. Hunt Chief Financial Officer and Principal Financial & Accounting Officer
Amos Hedt BA, PGradDip Chief Business Strategy Officer
Andrew Bright Executive Vice President of Brachytherapy
Annie J. Cheng Vice President of Investor Relations
David Hauser Ph.D. Senior Vice President of Clinical Operations
Dr. Frances L. Johnson M.D. Chief Innovation Officer
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer
Dr. Michael K. Schultz Ph.D. Chief Science Officer
Shane Cobb Executive Vice President of Operations

Latest SEC Filings

Date Type Title
Dec 06, 2024 4 Filing
Dec 04, 2024 4 Filing
Dec 04, 2024 4/A [Amend] Filing
Dec 04, 2024 4/A [Amend] Filing
Dec 04, 2024 8-K Current Report
Nov 27, 2024 4 Filing
Nov 27, 2024 4 Filing
Nov 26, 2024 4 Filing
Nov 21, 2024 8-K Current Report
Nov 15, 2024 8-K Current Report